Annual Reports

  • 10-K (Nov 29, 2013)
  • 10-K (Nov 29, 2012)
  • 10-K (Nov 29, 2011)
  • 10-K (Nov 29, 2010)
  • 10-K (Nov 30, 2009)
  • 10-K (Nov 26, 2008)

 
Quarterly Reports

 
8-K

 
Other

Meridian Bioscience 10-K 2006
EX-13
 

Exhibit 13
Meridian Bioscience, Inc. and Subsidiaries
SELECTED FINANCIAL DATA
Income Statement Information
                                         
    FY 2006     FY 2005     FY 2004     FY 2003     FY 2002  
 
Net sales
  $ 108,413     $ 92,965     $ 79,606     $ 65,864     $ 59,104  
 
Gross profit
    64,671       54,781       45,657       38,288       34,598  
Operating income (loss)
    26,881       20,216       14,658       12,789       9,994  
Net earnings (loss)
    18,325       12,565       9,185       7,018       5,031  
Basic earnings (loss) per share
  $ 0.70     $ 0.54     $ 0.41     $ 0.32     $ 0.23  
Diluted earnings (loss) per share
  $ 0.68     $ 0.52     $ 0.40     $ 0.31     $ 0.23  
Cash dividends declared per share
  $ 0.43     $ 0.31     $ 0.26     $ 0.23     $ 0.18  
Book value per share
  $ 3.62     $ 3.23     $ 1.47     $ 1.24     $ 1.11  
 
                                       
Balance Sheet Information
                                       
 
                                       
 
  30-Sep-06     30-Sep-05     30-Sep-04     30-Sep-03     30-Sep-02  
 
Current assets
  $ 81,169     $ 70,160     $ 36,111     $ 32,561     $ 30,375  
Current liabilities
    20,617       19,791       16,650       15,330       15,249  
Total assets
    120,955       110,569       69,322       66,420       65,095  
Long-term debt obligations
    1,803       2,684       17,093       21,505       23,626  
Shareholders’ equity
    94,777       83,768       32,932       27,484       24,381  
          (Amounts in thousands, except for per share data)
Forward Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should”, and similar expressions or the negative versions thereof and which also may be identified by their context. Such statements are based upon current expectations of the Company and speak only as of the date made. The Company assumes no obligation to publicly update any forward-looking statements. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
Meridian’s continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition. While Meridian has introduced a number of internally-developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Costs and difficulties in complying with laws and regulations administered by the United States Food and Drug Administration can result in unanticipated expenses and delays and interruptions to the sale of new and existing products. Changes in the relative strength or weakness of the U.S. dollar can change expected results. One of Meridian’s main growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses successfully integrated into Meridian’s operations.

 


 

CORPORATE PROFILE
Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral, and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded through Nasdaq’s National Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
MERIDIAN BIOSCIENCE, INC.
1

 


 

Corporate Data   Meridian Bioscience, Inc. and Subsidiaries
Corporate Headquarters
3471 River Hills Drive
Cincinnati, Ohio 45244
(513) 271-3700
Legal Counsel
Keating Muething & Klekamp PLL
Cincinnati, Ohio
Independent Public Accountants
Grant Thornton LLP
Cincinnati, Ohio
Transfer Agent, Registrar and Dividend Reinvestment Administration
Shareholders requiring a change of name, address or ownership of stock, as well as information about shareholder records, lost or stolen certificates, dividend checks, dividend direct deposit, and dividend reinvestment should contact: Computershare Investor Services LLC, P. O. Box 43078, Providence, RI 02940-3078; (888) 294-8217 or (312) 601-4332: e-mail web.queries@computershare.com; or submit your inquiries online through www.computershare.com/contactus.
Annual Meeting
The annual meeting of the shareholders will be held on Thursday, January 18, 2007 at 2:00 p.m. Eastern Time at the Holiday Inn Eastgate, 4501 Eastgate Boulevard, Cincinnati, OH 45245.
Directions to the Holiday Inn Eastgate can be found on our website: www.meridianbioscience.com.
Common Stock Information
NASDAQ National Market System Symbol: “VIVO.” Approximate number of record holders: 1000
The following table sets forth by calendar quarter the high and low sales prices of the Common Stock on the NASDAQ National Market System.
                                 
Years Ended September 30,   2006   2005
Quarter ended:   High   Low   High   Low
 
December 31
    23.010       17.760       12.633       8.367  
March 31
    27.740       20.120       13.707       9.687  
June 30
    28.000       21.460       14.320       8.853  
September 30
    25.340       19.240       20.970       9.915  
Directors and Officers
Directors
William J. Motto
Chairman of the Board and
Chief Executive Officer
John A. Kraeutler
President and
Chief Operating Officer
James A. Buzard, Ph.D.
Retired Executive
Vice President,
Merrell Dow
Pharmaceuticals, Inc.
Gary P. Kreider
Senior Partner,
Keating Muething &
Klekamp PLL
Robert J. Ready
Chairman of the Board
and President,
LSI Industries, Inc.
David C. Phillips
Co-founder,
Cincinnati Works, Inc.
Officers
William J. Motto
Chairman of the Board and
Chief Executive Officer
John A. Kraeutler
President and
Chief Operating Officer
Richard L. Eberly
Executive Vice President,
President Meridian Life
Science
Lawrence J. Baldini
Executive Vice President,
Operations and Information
Systems
Antonio A. Interno
Senior Vice President,
President and
Managing Director,
Meridian Bioscience Europe
Kenneth J. Kozak
Vice President,
Research and Development
Melissa A. Lueke
Vice President,
Chief Financial Officer
Susan D. Rolih
Vice President,
Regulatory Affairs and
Quality Assurance
Todd W. Motto
Vice President,
Sales and Marketing

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki